Abstract

This retrospective data analysis study aims to analyze the data collected during adjunctive homeopathy treatment of COVID-19 patients by the Homoeopathic medical officers (HMO) in Gujarat state-dedicated COVID-19 hospitals (DCH) during the first wave of the pandemic. The HMOs used the standard data collection forms/sheets to record each patient's demographic information, clinical symptoms, homoeopathic management, and outcome data. Data of all cases hospitalized with COVID-19 of any age, and both genders were included, and entries with missing values or incomplete/ incorrect information were excluded from the analysis. The outcome measure is the recovery duration, time to clinical improvement, worsening symptoms, and indicated homeopathic medicines. Data from 2581 cases analyzed showed clinical recovery time after adjunctive homeopathy as 05 days (IQR: 3-7); the Mean was 5.19 days (SD:4.62), with 80% of patients (2063 out of 2581) discharged between 0-7 days out of which more than 20.4% patients (419 out of 2063) having at least one of the comorbidities. Only 03 deaths of male patients above 50 years with comorbidities and 67 cases (2.6%) with worsening symptoms were reported. The homeopathic medicines used were <em>Arsenic album</em> in 73.0% and <em>Bryonia alba</em> in 17.6% of cases. Adjunctive Homoeopathy and standard care in COVID-19 patients had a promising role in the early relief of clinical symptoms and less progression into severity in the risk group of elderly patients with comorbidities. There were no reported adverse effects of taking the adjunctive Homoeopathy, making it a potential choice for integrated use in managing COVID-19 patients.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.